Covaxin Maker Gets $19 Million For Development Of 'Variant Proof' Vaccine - NDTV

CEPI on Tuesday said it will provide up to USD 19.3 million (about Rs 149 crore) to Bharat Biotech International, the University of Sydney, and Switzerland-based ExcellGene SA for the development of a "variant-proof" SARS-CoV-2 vaccine candidate.

CEPI will fund the initiative under its USD 200 million programme to advance the development of vaccines New Delhi: The Coalition for Epidemic Preparedness Innovations (CEPI) on Tuesday said it will… [+2276 chars]

full article...